CGIM
IPSC icon

Cannon Global Investment Management’s Century Therapeutics IPSC Stock Holding History

Cannon Global Investment Management’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-49,000
Closed -$111K – 70
2026
Q1 		$111K Buy
+49,000
New +$103K 0.22% 78

Other funds holding IPSC

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Cannon Global Investment Management's IPSC Position: Q2 2026 in Review

Cannon Global Investment Management sold out of Century Therapeutics (IPSC) in Q2 2026, closing a stake of 49,000 shares — an estimated $111K sold.

Cannon Global Investment Management first reported a position in IPSC in Q1 2026 and held it in 1 quarter. The position peaked at $111K in Q1 2026. 99 funds tracked by Wall St. Rank hold IPSC as of Q2 2026.

  • Cannon Global Investment Management reported no remaining Century Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Cannon Global Investment Management sold 49,000 Century Therapeutics shares in Q2 2026, an estimated $111K.
  • Cannon Global Investment Management first reported a position in Century Therapeutics in Q1 2026 and held it in 1 quarter.
  • Cannon Global Investment Management's Century Therapeutics position peaked at $111K in Q1 2026.
  • 99 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2026.

Based on Cannon Global Investment Management's 13F filing for Q2 2026, filed 30 Jul 2026.